Toronto, Ontario — SQI Diagnostics Inc. (“SQI” or the “Company”) (TSX-V: SQD; OTCQX: SQIDF),

a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics (“SQI”), today announced that it intends to extend the expiry of 2,965,000 outstanding common share purchase warrants (“the Warrants”) of the Company, which were issued in connection with the Company’s January 2014 private placement financing. The extension is subject to approval from the TSX Venture Exchange.

Each Warrant entitles the holder thereof to purchase one common share of the Company at any time until the close of business on January 26, 2016 at an exercise price of $0.65 per common shares. The Warrants will be amended, effective January 26, 2016, to extend the term of such Warrants until January 26, 2017. All other provisions of the Warrants will remain the same.

About SQI Diagnostics

SQI Diagnostics is a life sciences and diagnostics company that develops clinical grade multiplexed microarray and molecular assays run on its automated instrumentation for the pharmaceutical research, animal health, and clinical diagnostics markets. SQI develops custom research and diagnostic assays that are multiplexed; meaning the simplification, consolidation and automation of many individual tests into one. This increases sample throughput, reduces time, cost and chance for human error, and provides excellent data quality. For more information, please visit sqidiagnostics.com.